We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Court Refuses Ranbaxy Rehearing Bid In Lipitor Case

Law360 (October 23, 2006, 12:00 AM EDT) -- Ending another chapter in Pfizer Inc. and Ranbaxy Laboratories’ protracted battle over a generic version of blockbuster cholesterol drug Lipitor, an appeals court on Monday denied Ranbaxy’s petition for rehearing a decision in favor of Pfizer.

The U.S. Court of Appeals for the Federal Circuit issued a mixed ruling in the long-running battle over Lipitor, the world’s best-selling drug, on August 2.

The Federal Circuit’s ruling affirmed a lower court’s decision that one Pfizer patent covering the drug was valid, but struck down a second Lipitor-related...
To view the full article, register now.